Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12623000598684
Ethics application status
Approved
Date submitted
1/05/2023
Date registered
1/06/2023
Date last updated
22/07/2025
Date data sharing statement initially provided
1/06/2023
Type of registration
Prospectively registered

Titles & IDs
Public title
Co-Designing, Implementing, and Evaluating Supportive Care for Endometriosis (CodeEndo)
Scientific title
Co-designing and implementing 'CodeEndo': an online modular supportive care program and evaluating its impact on quality of life (and other biopsychosocial outcomes) for people living with endometriosis.
Secondary ID [1] 309550 0
Nil known
Universal Trial Number (UTN)
Trial acronym
CodeEndo
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Endometriosis 329839 0
Condition category
Condition code
Reproductive Health and Childbirth 326750 326750 0 0
Menstruation and menopause

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
CodeEndo is a online modular self-directed supportive care program for people living with endometriosis.

Phase 1: This phase will occur first, involving refining the structure and content of the CoDeEndo program, utilizing interviews and focus groups with consumers (i.e. those living with endometriosis) and collaboration with stakeholders (i.e. consumer representatives and endometriosis-related healthcare providers). The frequency and duration of interviews, focus groups, and collaboration will occur on a needs basis throughout this phase and may include for example review of intervention materials, meetings, and online platform feedback. In this phase the final intervention will be created and embedded into an online platform, with the total duration of this phase being 1.5 years.

Phase 2: This phase will follow phase 1, by evaluating the efficacy of the CoDeEndo program. The program will run for 8-weeks and includes 9 interventions each containing a number of sub-modules. The 9 interventions include - Mindfulness, Psychoeducation, Relaxation, Physiotherapy, Acceptance and Commitment Therapy, Hypnotherapy, Yoga, Cognitive Behavioral Therapy, and Dietary Education. Modules are comprised of a mix of video, audio, podcasts, and written resources. Participants will have access to all modules throughout the 8-weeks, allowing for observation of natural use. Participants will also be encouraged to practice (repeat) the modules throughout the 8-weeks. This means that participants can choose to spend as little as 5-mins to several hours per week accessing the CodeEndo Program. Participants will also receive weekly email reminders directing them to CoDeEndo. The specific goals of the intervention will vary for each person, depending on their individual symptoms, severity of disease, expectations and motivations, life experience, and what they want to achieve from the intervention. There are two strategies to monitor adherence to the intervention. 1) The website used to deliver the intervention has an inbuilt tracking system, which is able to provide detailed data regarding participant intervention usage. 2) Also embedded into the website are questions are the end of each module/week asking participants to self-report their usage of the intervention.
Intervention code [1] 325976 0
Behaviour
Intervention code [2] 325977 0
Lifestyle
Intervention code [3] 326054 0
Treatment: Other
Comparator / control treatment
Waitlist Control: Participants randomised to the waitlist control group will continue their treatment-as-usual and be offered access to the CodeEndo program at the end of providing their final follow-up questionnaire (6-months post-randomisation).
Control group
Active

Outcomes
Primary outcome [1] 334604 0
Endometriosis-related quality of life measured by the 30-item endometriosis Health Profile (EHP-30)
Timepoint [1] 334604 0
Baseline, post-treatment at 8 weeks and 6 months (primary endpoint) since baseline
Primary outcome [2] 334605 0
Quality of life will be measured by the Euroqol (EQ)-5D-5L
Timepoint [2] 334605 0
Baseline, post-treatment at 8 weeks and 6 months (primary endpoint) since baseline
Secondary outcome [1] 421378 0
Self-efficacy with the Pain Self-Efficacy Questionnaire (PSEQ)
Timepoint [1] 421378 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [2] 421379 0
Psychological symptoms with the Depression Anxiety Stress Scale - 21 items (DASS-21)
Timepoint [2] 421379 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [3] 421380 0
Fatigue with the Fatigue Symptom Inventory (FSI)
Timepoint [3] 421380 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [4] 421381 0
Menstrual symptoms with the Menstrual Symptoms Questionnaire (MSQ)
Timepoint [4] 421381 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [5] 421382 0
Health utilization and cost data via a consumer health economics questionnaires and participants Services Australia usage - this questionnaire has been designed specifically for this study.
Timepoint [5] 421382 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [6] 421383 0
Gastrointestinal symptom data will be collected using the Gastrointestinal Symptom Rating Scale
Timepoint [6] 421383 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [7] 421384 0
Diet data on a 3-day food diary (composite: energy, nutrient and FODMAP intake on Foodworks and the Monash FODMAP calculator)
Timepoint [7] 421384 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [8] 441441 0
Exercise via the Brief Physical Activity Scale
Timepoint [8] 441441 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [9] 441442 0
Bladder symptoms via the Interstitial Cystitis Symptom and Problem Questionnaire.
Timepoint [9] 441442 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [10] 441444 0
Sleep via the Jenkins Sleep Questionnaire
Timepoint [10] 441444 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [11] 441446 0
Physical well-being via Numerical Rating Scale
Timepoint [11] 441446 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [12] 441448 0
Pain via numerical rating scales.
Timepoint [12] 441448 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [13] 441450 0
Most Bothersome Symptom via Numerical Rating Scale
Timepoint [13] 441450 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [14] 441452 0
Treatment changes via open-ended self-report question.
Timepoint [14] 441452 0
Baseline, post-treatment at 8 weeks and 6 months since baseline
Secondary outcome [15] 441454 0
Mental well-being via Numerical Rating Scale
Timepoint [15] 441454 0
Baseline, post-treatment at 8 weeks and 6 months since baseline

Eligibility
Key inclusion criteria
Trial Participants:
Inclusion criteria:
- Can provide proof of endometriosis diagnosis. (This can include a letter from a doctor, results of histology, operation reports, ultrasound scan, or any other medical document confirming their diagnosis).
- Be Aged 18+.
- Live in Australia.
- Not pregnant.
- Proficient in English.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
Trial Participants
Exclusion criteria:
- Recent endometriosis-related surgery within the last 3 months.
- Currently participating in another research study related to pelvic pain, endometriosis or hypnotherapy.
- No psychological distress (Screened via K10 - score of 15 or below).
- Extreme dissociative experiences (screened via Brief Dissociative Experiences Scale (DES-B) - score of 2.5 or above).
- Cognitive impairment (Screened via psychologist interview)
- Suicide/Self-harm (Screened via psychologist interview)
- Substance Use/Dependence (Screened via psychologist interview)
- Bipolar I or Bipolar II (Screened via psychologist interview)
- Schizophrenia/Psychosis (Screened via psychologist interview)
- Post Traumatic Stress Disorder (Screened via psychologist interview)
- Borderline Personality Disorder (Screened via psychologist interview)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
An automated block randomisation sequence with variable block size will be embedded into Qualtrics for allocation concealment. The study biostatistician will not be involved in participant recruitment and will be blinded to group allocation.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Consenting participants will be randomly assigned (1:1 ratio) to CodeEndo or Wait-List Control following completion of baseline questionnaire. A block randomisation sequence with variable block size will be embedded into Qualtrics for allocation concealment.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Statistical analyses is planned to be conducted on an intention-to-treat basis. The intervention effect over time (baseline T1, 8-weeks T2, and 6-months T3) on the primary outcomes (EHP-30 and EQ-5D-5L) and the secondary outcomes (all other biopsychosocial outcomes) will be estimated using linear mixed models. The models will include group (intervention, control), time (T1, T2, T3), and group x time interaction effect.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
15/01/2025
Actual
27/09/2023
Date of last participant enrolment
Anticipated
1/11/2026
Actual
Date of last data collection
Anticipated
1/06/2027
Actual
Sample size
Target
352
Accrual to date
56
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 313742 0
Government body
Name [1] 313742 0
National Health and Medical Research Council
Country [1] 313742 0
Australia
Primary sponsor type
University
Name
Deakin University
Address
Deakin University
Geelong Waurn Ponds Campus
Locked Bag 20000
Geelong VIC 3220
Country
Australia
Secondary sponsor category [1] 315558 0
None
Name [1] 315558 0
Address [1] 315558 0
Country [1] 315558 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 312914 0
Deakin University Human Research Ethics Committee
Ethics committee address [1] 312914 0
Ethics committee country [1] 312914 0
Australia
Date submitted for ethics approval [1] 312914 0
22/06/2023
Approval date [1] 312914 0
04/08/2023
Ethics approval number [1] 312914 0
2024-157

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 126314 0
Prof Antonina Mikocka-Walus
Address 126314 0
Deakin University School of Psychology 221 Burwood Hwy Burwood 3125 VIC
Country 126314 0
Australia
Phone 126314 0
+61392468575
Fax 126314 0
Email 126314 0
[email protected]
Contact person for public queries
Name 126315 0
Dr Shannon Bennetts
Address 126315 0
Deakin University School of Psychology 221 Burwood Hwy Burwood 3125 VIC
Country 126315 0
Australia
Phone 126315 0
+61392468575
Fax 126315 0
Email 126315 0
[email protected]
Contact person for scientific queries
Name 126316 0
Prof Antonina Mikocka-Walus
Address 126316 0
Deakin University School of Psychology 221 Burwood Hwy Burwood 3125 VIC
Country 126316 0
Australia
Phone 126316 0
+61392468575
Fax 126316 0
Email 126316 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: We believe participants (a chronically ill cohort) may be reluctant to participate if we decided to share their health-related data. Further, we are initiating a program of research in this area and want our team to be able to use the data in future publications. This is not a large dataset and thus by opening it to others we might lose the opportunity to publish the data ourselves.

Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
Conditions for requesting access:
What individual participant data might be shared?
What types of analyses could be done with individual participant data?
When can requests for individual participant data be made (start and end dates)?
From:
To:
Where can requests to access individual participant data be made, or data be obtained directly?
Are there extra considerations when requesting access to individual participant data?


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.